Market capitalization | €1.50b |
Enterprise Value | €-1.79b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 8.07 |
EV/Sales (TTM) EV/Sales | -6.21 |
P/S ratio (TTM) P/S ratio | 5.20 |
P/B ratio (TTM) P/B ratio | 0.54 |
Revenue (TTM) Revenue | €288.19m |
EBIT (operating result TTM) EBIT | €-351.89m |
As a Free StocksGuide user, you can view scores for all 6,791 stocks worldwide.
12 Analysts have issued a Galapagos forecast:
12 Analysts have issued a Galapagos forecast:
Mar '25 |
+/-
%
|
||
Revenue | 288 288 |
47%
47%
|
|
Gross Profit | 242 242 |
54%
54%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -352 -352 |
68%
68%
|
Net Profit | -170 -170 |
11%
11%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Head office | Belgium |
CEO | Paulus Stoffels |
Employees | 704 |
Founded | 1999 |
Website | www.glpg.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.